Mergers and Inquisitions

NOVEMBER 1, 2023

When you hear the words “healthcare private equity,” two thoughts probably come to mind: Wait a minute, isn’t healthcare a risky/growth-oriented sector? In most of the world, healthcare is either government-run or a mixed public/private sector. Are there many private healthcare companies for PE firms to acquire?

Private Equity 59

Private Equity Healthcare Equities Middle Market 59

Mergers and Inquisitions

MARCH 13, 2024

This style is about purchasing minority stakes in cash-flow-negative-but-high-growth companies that want to scale and eventually go public or sell (think: Uber or Airbnb before their IPOs). Many of these firms use debt to fund deals, and they complete bolt-on acquisitions for portfolio companies. What accounts for the difference?

Private Equity 105

Private Equity Equities Capital Portfolio 105

Mergers and Inquisitions

SEPTEMBER 20, 2023

Firm-Specific and Process Questions – What do you think about our portfolio? You can also link this back to tech or healthcare companies you’ve advised or earlier-stage businesses where your work made a difference. A: This one should relate directly to your research on the firm, including their target markets and portfolio companies.

Capital 59

Capital Valuation Investment Portfolio 59

InvestmentBank.com

JANUARY 14, 2021

In September 2020, the National Bureau of Economic Research released a working paper including an industry survey citing 900+ VC firms; this paper revealed a consensus that many portfolio companies were performing quite well in the face of Covid-19 and less than 10% were performing at levels that would raise significant concerns [3] [10].

Capital 40

Capital IPO S&P Hospitality 40

Mergers and Inquisitions

JULY 31, 2024

Today, you could put most private equity activity in industrials into a few main categories: Consolidation / Roll-Up Plays – The idea is to acquire smaller companies to consolidate the parent company’s market position and become more appealing in an eventual IPO or M&A deal. Note that not all “large” funds do industrial deals.

Private Equity 66

Private Equity Equities Middle Market Debt 66

Cooley M&A

JANUARY 25, 2023

Although there were 104 initial public offerings of biotechnology companies in 2021 that raised nearly $15 billion in funds, 2022 saw only 22 such IPOs collectively raising less than $2 billion. 2022 was the busiest year for activism in the past four years, and the healthcare and life sciences industry was no exception. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 23, 2024

Strained access to public markets and funding The IPO market remained relatively inactive in 2023, leading many life sciences companies looking to raise funds to turn to other exit strategies. Additional major acquisitions of 2023 included Pfizer’s acquisition of Seagen for $43 billion and Merck’s acquisition of Prometheus for $10.8

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52